InspireMD, Inc. (NSPR) Financial Ratios
17 years of historical data (2009–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.54
-6% vs avg
5yr avg: 1.64
30Y Low0.4·High3.1
ROE
↓
-106.9%
↑-34% vs avg
5yr avg: -79.9%
30Y Low-434%·High-65%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NSPR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
InspireMD, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $54M | $131M | $110M | $68M | $7M | $22M | $8M | $2M | $4M | $5M | $3M |
| Enterprise Value | $48M | $124M | $94M | $60M | $4M | $11M | $-3532525 | $-2241838 | $-5691720 | $1M | $-2211000 |
| P/E Ratio → | -1.53 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.06 | 14.56 | 15.73 | 10.99 | 1.31 | 4.94 | 3.10 | 0.61 | 1.03 | 1.75 | 1.39 |
| P/B Ratio | 1.54 | 2.37 | 3.06 | 1.73 | 0.39 | 0.66 | 0.63 | 0.42 | 0.42 | 1.77 | 0.65 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NSPR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 13.82 | 13.37 | 9.69 | 0.73 | 2.53 | -1.42 | -0.60 | -1.58 | 0.40 | -1.17 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NSPR Profitability
Margins and return-on-capital ratios measuring operating efficiency
InspireMD, Inc. earns an operating margin of -547.0%. Operating margins have compressed from -340.7% to -547.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -106.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.5% | 29.5% | 21.5% | 29.1% | 21.6% | 16.8% | 3.3% | 20.3% | 27.6% | 21.2% | 5.4% |
| Operating Margin | -547.0% | -547.0% | -478.0% | -340.7% | -361.9% | -327.4% | -417.7% | -263.8% | -211.4% | -298.2% | -403.8% |
| Net Profit Margin | -543.3% | -543.3% | -456.6% | -321.0% | -357.6% | -331.9% | -424.3% | -269.8% | -201.1% | -305.6% | -446.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -106.9% | -106.9% | -84.7% | -70.0% | -72.6% | -65.3% | -120.2% | -141.9% | -126.0% | -249.2% | -1539.8% |
| ROA | -84.0% | -84.0% | -67.8% | -55.1% | -57.5% | -51.9% | -76.2% | -90.6% | -78.7% | -108.8% | -111.4% |
| ROIC | -108.3% | -108.3% | -98.6% | -69.2% | -75.7% | -93.4% | -864.5% | -5598.5% | — | — | — |
| ROCE | -100.4% | -100.4% | -83.0% | -69.1% | -68.1% | -59.5% | -99.6% | -121.7% | -117.2% | -199.4% | -438.2% |
NSPR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.06 | 0.04 | 0.09 | 0.04 | 0.12 | 0.19 | — | — | 0.66 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.12 | -0.46 | -0.20 | -0.17 | -0.32 | -0.92 | -0.84 | -1.07 | -1.36 | -1.20 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -93.73 | -64.88 | -49.08 | — | -46.32 | -9.53 |
Net cash position: cash ($9M) exceeds total debt ($2M)
NSPR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
InspireMD, Inc.'s current ratio of 5.74x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.42x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 7.34x to 5.74x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.74 | 5.74 | 5.28 | 7.34 | 4.21 | 8.53 | 4.14 | 2.51 | 3.91 | 2.08 | 1.80 |
| Quick Ratio | 5.42 | 5.42 | 4.94 | 6.99 | 3.89 | 8.27 | 3.76 | 2.11 | 3.52 | 1.86 | 1.69 |
| Cash Ratio | 5.06 | 5.06 | 4.51 | 6.48 | 3.51 | 7.83 | 3.41 | 1.77 | 3.21 | 1.49 | 1.57 |
| Asset Turnover | — | 0.13 | 0.15 | 0.13 | 0.21 | 0.11 | 0.14 | 0.38 | 0.29 | 0.45 | 0.20 |
| Inventory Turnover | 1.86 | 1.86 | 2.14 | 2.09 | 2.50 | 3.27 | 1.70 | 2.40 | 2.30 | 4.08 | 3.58 |
| Days Sales Outstanding | — | 104.39 | 117.38 | 144.24 | 88.02 | 112.79 | 138.80 | 95.44 | 83.12 | 112.37 | 98.86 |
NSPR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
InspireMD, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 81.6% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 81.6% | 0.0% | 0.0% |
| Shares Outstanding | — | $73M | $42M | $24M | $8M | $7M | $2M | $139331 | $30769 | $1978 | $56 |
Peer Comparison
Compare NSPR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NSPRYou | $54M | -1.5 | — | — | 29.5% | -547.0% | -106.9% | -108.3% | — |
 ELMD | $222M | 31.2 | 19.1 | 20.1 | 78.1% | 15.1% | 17.2% | 25.6% | 0.0 |
 ATEC | $1B | -8.1 | 3752.1 | 422.6 | 69.6% | -10.7% | -630.7% | -12.6% | 1425.2 |
 ANGO | $469M | -13.6 | — | — | 53.9% | -13.7% | -17.5% | -22.9% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 MDT | $100B | 21.6 | 14.3 | 19.3 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 ABT | $151B | 11.4 | 15.8 | 23.8 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
 ZBH | $16B | 23.5 | 9.5 | 11.1 | 61.6% | 16.5% | 5.6% | 5.4% | 3.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 17 years · Updated daily
See NSPR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NSPR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NSPR vs ELMD
Side-by-side business, growth, and profitability comparison vs Electromed, Inc..
Start ComparisonNSPR — Frequently Asked Questions
Quick answers to the most common questions about buying NSPR stock.
What is InspireMD, Inc.'s P/E ratio?
InspireMD, Inc.'s current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
What is InspireMD, Inc.'s ROE?
InspireMD, Inc.'s return on equity (ROE) is -106.9%. The historical average is -185.1%.
Is NSPR stock overvalued?
Based on historical data, InspireMD, Inc. is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are InspireMD, Inc.'s profit margins?
InspireMD, Inc. has 29.5% gross margin and -547.0% operating margin.